China Resources Double-Crane Pharmaceutical Co Ltd (600062) — Cash Flow Quality Index
China Resources Double-Crane Pharmaceutical Co Ltd (600062) has a Cash Flow Quality Index of 1.30x as of September 2025. Operating cash flow of CN¥487.90 Million exceeds net income of CN¥374.04 Million, indicating high earnings quality where cash backs reported profits. Explore 600062 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
China Resources Double-Crane Pharmaceutical Co Ltd Cash Flow Quality Index (1998–2024)
Historical Cash Flow Quality Index for China Resources Double-Crane Pharmaceutical Co Ltd across 26 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check China Resources Double-Crane Pharmaceuti tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for China Resources Double-Crane Pharmaceutical Co Ltd (1998–2024)
Year-by-year earnings quality comparison for China Resources Double-Crane Pharmaceutical Co Ltd. For live market cap and the full company financial profile, see China Resources Double-Crane Pharmaceuti (600062) total market value.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.11x | CN¥1.83 Billion | CN¥1.65 Billion | ▼ -11.2% |
| 2023 | 1.25x | CN¥1.65 Billion | CN¥1.33 Billion | ▲ +12.8% |
| 2022 | 1.10x | CN¥1.34 Billion | CN¥1.22 Billion | ▼ -20.0% |
| 2021 | 1.38x | CN¥1.34 Billion | CN¥972.13 Million | ▲ +2.8% |
| 2020 | 1.34x | CN¥1.36 Billion | CN¥1.01 Billion | ▼ -0.6% |
| 2019 | 1.35x | CN¥1.44 Billion | CN¥1.07 Billion | ▼ -9.1% |
| 2018 | 1.48x | CN¥1.47 Billion | CN¥989.45 Million | ▲ +10.3% |
| 2017 | 1.35x | CN¥1.19 Billion | CN¥882.10 Million | ▲ +29.0% |
| 2016 | 1.04x | CN¥771.25 Million | CN¥739.25 Million | ▼ -1.1% |
| 2015 | 1.05x | CN¥701.35 Million | CN¥664.82 Million | ▼ -20.2% |
| 2014 | 1.32x | CN¥718.38 Million | CN¥543.66 Million | ▲ +111.3% |
| 2013 | 0.63x | CN¥546.24 Million | CN¥873.44 Million | ▼ -0.4% |
| 2012 | 0.63x | CN¥396.05 Million | CN¥630.55 Million | ▼ -32.2% |
| 2011 | 0.93x | CN¥511.53 Million | CN¥552.52 Million | ▼ -3.2% |
| 2010 | 0.96x | CN¥509.67 Million | CN¥533.00 Million | ▲ +29.6% |
| 2009 | 0.74x | CN¥342.01 Million | CN¥463.45 Million | ▼ -11.8% |
| 2008 | 0.84x | CN¥331.71 Million | CN¥396.46 Million | ▲ +62.6% |
| 2007 | 0.51x | CN¥235.46 Million | CN¥457.61 Million | ▼ -69.6% |
| 2006 | 1.69x | CN¥303.71 Million | CN¥179.22 Million | ▲ +130.3% |
| 2005 | 0.74x | CN¥139.78 Million | CN¥189.97 Million | ▼ -74.5% |
| 2003 | 2.89x | CN¥148.94 Million | CN¥51.55 Million | ▲ +200.2% |
| 2002 | 0.96x | CN¥140.63 Million | CN¥146.15 Million | ▲ +10.6% |
| 2001 | 0.87x | CN¥141.01 Million | CN¥162.05 Million | ▼ -30.2% |
| 2000 | 1.25x | CN¥172.81 Million | CN¥138.60 Million | ▼ -28.7% |
| 1999 | 1.75x | CN¥131.54 Million | CN¥75.25 Million | ▲ +875.2% |
| 1998 | -0.23x | CN¥-13.78 Million | CN¥61.13 Million | — |